CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Standard
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. / Rau, Thomas; Wohlleben, Gerlinde; Wuttke, Henrike; Thuerauf, Norbert; Lunkenheimer, Jens; Lanczik, Mario; Eschenhagen, Thomas.
in: CLIN PHARMACOL THER, Jahrgang 75, Nr. 5, 5, 2004, S. 386-393.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
AU - Rau, Thomas
AU - Wohlleben, Gerlinde
AU - Wuttke, Henrike
AU - Thuerauf, Norbert
AU - Lunkenheimer, Jens
AU - Lanczik, Mario
AU - Eschenhagen, Thomas
PY - 2004
Y1 - 2004
N2 - OBJECTIVE: Treatment with antidepressants is frequently associated with adverse effects or insufficient clinical response. Several antidepressants are metabolized by cytochrome P450 (CYP) 2D6. The activity of this enzyme markedly varies among individuals from poor to ultrarapid metabolism on the basis of the polymorphism of the CYP2D6 gene. This association study investigated whether the CYP2D6 genotype distribution differs from that of the German white population either in patients with marked adverse effects or in nonresponders during treatment with antidepressants metabolized by CYP2D6. METHODS: By use of a retrospective, naturalistic approach, outpatient practices and hospitals in southern Germany were asked to report on patients who either had had adverse drug effects or were nonresponsive during treatment with CYP2D6-dependent antidepressants. CYP2D6 genotyping was performed by a panel of polymerase chain reaction techniques. Poor and intermediate metabolizer alleles, as well as allelic duplications of CYP2D6, were detected. RESULTS: Of 28 patients with adverse effects during treatment with a CYP2D6-dependent antidepressant, 8 (29%) had 2 inactive alleles and thus were poor metabolizers. This is a 4-fold increase as compared with the German population (P
AB - OBJECTIVE: Treatment with antidepressants is frequently associated with adverse effects or insufficient clinical response. Several antidepressants are metabolized by cytochrome P450 (CYP) 2D6. The activity of this enzyme markedly varies among individuals from poor to ultrarapid metabolism on the basis of the polymorphism of the CYP2D6 gene. This association study investigated whether the CYP2D6 genotype distribution differs from that of the German white population either in patients with marked adverse effects or in nonresponders during treatment with antidepressants metabolized by CYP2D6. METHODS: By use of a retrospective, naturalistic approach, outpatient practices and hospitals in southern Germany were asked to report on patients who either had had adverse drug effects or were nonresponsive during treatment with CYP2D6-dependent antidepressants. CYP2D6 genotyping was performed by a panel of polymerase chain reaction techniques. Poor and intermediate metabolizer alleles, as well as allelic duplications of CYP2D6, were detected. RESULTS: Of 28 patients with adverse effects during treatment with a CYP2D6-dependent antidepressant, 8 (29%) had 2 inactive alleles and thus were poor metabolizers. This is a 4-fold increase as compared with the German population (P
M3 - SCORING: Zeitschriftenaufsatz
VL - 75
SP - 386
EP - 393
JO - CLIN PHARMACOL THER
JF - CLIN PHARMACOL THER
SN - 0009-9236
IS - 5
M1 - 5
ER -
